Yusuke Nakamura to Feasibility Studies
This is a "connection" page, showing publications Yusuke Nakamura has written about Feasibility Studies.
Connection Strength
0.067
-
A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors. PLoS One. 2018; 13(1):e0187878.
Score: 0.034
-
Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci. 2009 Aug; 100(8):1502-9.
Score: 0.018
-
Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4. Cancer Sci. 2006 Nov; 97(11):1191-7.
Score: 0.015